Baird said success in the Myozyme LOTS trial removes a major overhang for Genzyme (Nasdaq: GENZ). The firm said ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE